共 128 条
[1]
Bruix J(2005)AASLD practice guideline: management of hepatocellular carcinoma Hepatology 42 1208-1236
[2]
Sherman M(2011)AASLD practice guideline: management of hepatocellular carcinoma: an update Hepatology 53 1020-1022
[3]
Bruix J(2001)Clinical management of hepatocellular carcinoma: conclusions of the Barcelona-2000 EASL conference J Hepatol 35 421-430
[4]
Sherman M(1999)Accurate preoperative evaluation of liver mass lesions without fine-needle biopsy Hepatology 30 889-893
[5]
Bruix J(2001)Resection of hepatocellular carcinoma without preoperative tumour biopsy Ann Surg 234 206-209
[6]
Sherman M(1992)Preclinical evaluation of Gd-EOB-DTPA as a contrast agent in MR imaging of the hepatobiliary system Radiology 183 59-64
[7]
Llovet JM(1992)Gadolinium-ethoxybenzyl-DTPA: a new liver-specific magnetic resonance contrast agent-kinetic and enhancement patterns in normal and cholestatic rats Invest Radiol 27 612-619
[8]
Torzilli G(1993)Gadolinium-ethoxybenzyl-DTPA: a new liver-directed magnetic resonance contrast agent-absence of acute epatotoxic, cardiovascular, or immunologic effects Invest Radiol 28 26-32
[9]
Minagawa M(1991)A new lipophilic gadolinium chelate as a tissue-specific contrast medium for MRI Magn Reson Med 22 222-228
[10]
Takayama T(1994)Elimination of Gd-EOB-DTPA in severely impaired liver and kidney excretory function Invest Radiol 29 213-216